| Autor: |
Hart, Bryan E., Asrican, Rose, Lim, So-Yon, Sixsmith, Jaimie D., Lukose, Regy, Souther, Sommer J. R., Rayasam, Swati D. G., Saelens, Joseph W., Chen, Ching-ju, Seay, Sarah A., Berney-Meyer, Linda, Magtanong, Leslie, Vermeul, Kim, Pajanirassa, Priyadharshini, Jimenez, Amanda E., Ng, Tony W., Tobin, David M., Porcelli, Steven A., Larsen, Michelle H., Schmitz, Joern E., Haynes, Barton F., Jacobs, William R., Lee, Sunhee, Frothingham, Richard |
| Zdroj: |
Clinical and Vaccine Immunology (formerly CDLI); May 2015, Vol. 22 Issue: 7 p726-741, 16p |
| Abstrakt: |
ABSTRACTThe well-established safety profile of the tuberculosis vaccine strain, Mycobacterium bovisbacille Calmette-Guérin (BCG), makes it an attractive vehicle for heterologous expression of antigens from clinically relevant pathogens. However, successful generation of recombinant BCG strains possessing consistent insert expression has encountered challenges in stability. Here, we describe a method for the development of large recombinant BCG accession lots which stably express the lentiviral antigens, human immunodeficiency virus (HIV) gp120 and simian immunodeficiency virus (SIV) Gag, using selectable leucine auxotrophic complementation. Successful establishment of vaccine stability stems from stringent quality control criteria which not only screen for highly stable complemented BCG ?leuCDtransformants but also thoroughly characterize postproduction quality. These parameters include consistent production of correctly sized antigen, retention of sequence-pure plasmid DNA, freeze-thaw recovery, enumeration of CFU, and assessment of cellular aggregates. Importantly, these quality assurance procedures were indicative of overall vaccine stability, were predictive for successful antigen expression in subsequent passaging both in vitroand in vivo, and correlated with induction of immune responses in murine models. This study has yielded a quality-controlled BCG ?leuCDvaccine expressing HIV gp120 that retained stable full-length expression after 1024-fold amplification in vitroand following 60 days of growth in mice. A second vaccine lot expressed full-length SIV Gag for >1068-fold amplification in vitroand induced potent antigen-specific T cell populations in vaccinated mice. Production of large, well-defined recombinant BCG ?leuCDlots can allow confidence that vaccine materials for immunogenicity and protection studies are not negatively affected by instability or differences between freshly grown production batches. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
